NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, Forecast & News

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. View Allena Pharmaceuticals' Earnings History.

Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Allena Pharmaceuticals.

4 analysts have issued 12-month target prices for Allena Pharmaceuticals' shares. Their forecasts range from $4.00 to $31.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.

Press coverage about ALNA stock has trended very negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a coverage optimism score of -3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Allena Pharmaceuticals.

Allena Pharmaceuticals saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 553,300 shares, a decline of 10.2% from the January 15th total of 616,200 shares. Based on an average trading volume of 469,700 shares, the short-interest ratio is presently 1.2 days. Currently, 4.9% of the shares of the company are short sold. View Allena Pharmaceuticals' Current Options Chain.

Some companies that are related to Allena Pharmaceuticals include CASI Pharmaceuticals (CASI), LogicBio Therapeutics (LOGC), Jounce Therapeutics (JNCE), Verona Pharma (TARA), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Brainstorm Cell Therapeutics (BCLI), Solid Biosciences (SLDB), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Axcella Health (AXLA), Gamida Cell (GMDA), Cidara Therapeutics (CDTX) and Applied Genetic Technologies (AGTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Amarin (AMRN), Clearside Biomedical (CLSD), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Adamas Pharmaceuticals (ADMS) and Anavex Life Sciences (AVXL).

(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.03%), Geode Capital Management LLC (0.45%), Wedbush Securities Inc. (0.21%), Banco Bilbao Vizcaya Argentaria S.A. (0.16%), Algert Global LLC (0.16%) and Goldman Sachs Group Inc. (0.14%). View Institutional Ownership Trends for Allena Pharmaceuticals.

ALNA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Allena Pharmaceuticals.

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, Banco Bilbao Vizcaya Argentaria S.A., Algert Global LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Allena Pharmaceuticals.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNA stock can currently be purchased for approximately $2.16.

Allena Pharmaceuticals has a market capitalization of $50.70 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals.

The official website for Allena Pharmaceuticals is http://www.allenapharma.com/.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.